The Acticor Sky CRT-DX, which secured FDA approval in April, has officially made its debut in the United States.

Medtronic is recalling more than 700 OmniaSecure defibrillation leads, urging customers to quarantine and return them. The FDA has ruled this is a Class II recall. No adverse events have been reported.

The UltiSynq defibrillation lead from Abbott gives clinicians a new option for left bundle branch area pacing. The device has also received CE mark approval.

Researchers tracked data from nearly 6,000 patients being seen for suspected atrial fibrillation, coronary artery disease or heart failure. These data suggest patients can feel at ease meeting their cardiologist for the first time by video or telephone.

Researchers tracked data from more than 50 million hospital discharges. Overall, legalizing recreational cannabis was linked to more patients being hospitalized for myocardial infarction, atrial fibrillation and heart failure.

Medtronic identified an issue with its CareLink SmartSync device manager providing inaccurate longevity estimates for certain leadless pacemakers. Customers can download a software update to resolve the issue going forward.

The instructions for Abbott's Amplatzer Amulet Left Atrial Appendage Occluder now include more details about minimizing the risk of pulmonary artery injury. This a Class II recall, but no devices need to be returned.

These findings call into question the types of screenings firefighters should undergo to detect potential heart problems.

The new device from Chicago-based Parasol Med Tech uses gel to seal the left atrial appendage. It leaves no metal hardware behind.

These pacemakers were built with conduction system pacing in mind, giving clinicians several new tools for the management of heart patients. 

California-based Masimo received the clearance just a few months after being acquired by Danaher Corporation in a deal worth approximately $9.9 billion.